Controversies in the Treatment of Peripheral T-cell Lymphoma. Issue 5 (1st October 2020)

• Record Type: Journal Article
• Authors: Bachy, Emmanuel; Broccoli, Alessandro; Dearden, Claire; de Leval, Laurence; Gaulard, Philippe; Koch, Raphael; Morschhauser, Franck; Trümper, Lorenz; Zinzani, Pier Luigi
• Is Part Of: HemaSphere. Volume 4:Issue 5(2020)
• Page Start: e461
• Publication Date: 2020-10-01
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/HS9.0000000000000461
• Languages: English
• ISSNs: 2572-9241

Abstract

Abstract : Abstract: Peripheral T-cell lymphomas are a heterogeneous group of rare diseases with an aggressive behavior and dismal prognosis. Their classification is complex and still evolving, and several biomolecular markers now help refine the prognosis of specific disease entities, although still have limited impact in tailoring the treatment. First-line treatment strategies can cure only a minority of patients and relapsed-refractory disease still represents the major cause of failure. Frontline autologous transplantation may have an impact in the consolidation of response; however, its role is still questioned as far as complete responses obtained after induction chemotherapy are concerned. Newer drugs are now being evaluated in clinical trials, but effective salvage strategies for those who experience treatment failures are lacking. Here we review and discuss the most controversial aspects of diagnosis and treatment of peripheral T-cell lymphomas.